Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers

9Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Previous studies indicate that sumatriptan is not effective when second messenger levels are high as after cilostazol provocation. Therefore, we have conducted the present study, where sumatriptan is administrated as pretreatment before cAMP increases due to cilostazol intake. Our hypothesis was that pretreatment with sumatriptan would have a significant effect against cilostazol induced headache in healthy volunteers. Methods: In a double-blind, randomized, crossover design, 30 healthy volunteers of both sexes received cilostazol 200 mg on two separate days, each day preceded by oral sumatriptan (2 × 50 mg) or placebo. Headache response and accompanying symptoms were registered in a questionnaire by the participants themselves. Results: Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale). There was no significant difference in headache score 2 h (p = 0.67) or 4 h (p = 0.1) after treatment between the 2 days. Median peak headache score was 1.5 (range 0-5) on the sumatriptan day and 2 (range 0-7) on the placebo day (p = 0.26). Conclusion: Pre-treatment with sumatriptan prevents cilostazol induced headache from developing. However, the placebo group did not develop enough headache to get statistical significant results. The cilostazol pre-treatment model is valuable for experimental headache research and perhaps for testing drugs with another mechanism of action. Trial registration: ClinicalTrials.gov Identifier: NCT03156920.

References Powered by Scopus

The International Classification of Headache Disorders, 3rd edition (beta version)

6206Citations
N/AReaders
Get full text

Cilostazol (Pletal®): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake

191Citations
N/AReaders
Get full text

Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase

86Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment

36Citations
N/AReaders
Get full text

Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache

15Citations
N/AReaders
Get full text

Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Falkenberg, K., & Olesen, J. (2018). Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. Journal of Headache and Pain, 19(1). https://doi.org/10.1186/s10194-018-0890-y

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

55%

Lecturer / Post doc 2

18%

Researcher 2

18%

Professor / Associate Prof. 1

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

67%

Nursing and Health Professions 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Design 1

7%

Save time finding and organizing research with Mendeley

Sign up for free